Raltegravir

Generic Name: Raltegravir

Brand Names: Isentress

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₆O_₅

CAS Number: 518048-05-0

Unique Ingredient Identifier: 22VKV8053U

Background: Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication: For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: Post-exposure prophylaxis for occupational exposure to HIV therapy

Clinical Trials

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily

Phase 4

Completed

Conditions: HIV Infections
HIV-1 Infection

Interventions: Drug: Raltegravir
Drug: Etravirine

First Posted Date: 2010-05-12

Last Posted Date: 2011-02-08

Lead Sponsor: Hospitales Universitarios Virgen del Rocío

Target Recruit Count: 16

Registration Number: NCT01121809

Locations: 🇪🇸
Hospitales Universitarios Virgen del Rocio, Sevilla, Spain

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

Phase 4

Conditions: HIV Infections
Hepatitis C

Interventions: Drug: Atazanavir/Ritonavir
Drug: Raltegravir

First Posted Date: 2010-04-16

Last Posted Date: 2011-07-21

Lead Sponsor: St. James's Hospital, Ireland

Target Recruit Count: 40

Registration Number: NCT01105611

Locations: 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪
Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Raltegravir
Drug: GSK2248761
Drug: GSK2248761 + Raltegravir

First Posted Date: 2010-04-12

Last Posted Date: 2017-09-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 15

Registration Number: NCT01101893

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men

Phase 4

Completed

Conditions: HIV Prevention
HIV Infections

Interventions: Drug: Raltegravir

First Posted Date: 2010-03-16

Last Posted Date: 2014-04-17

Lead Sponsor: Andrew Carr

Target Recruit Count: 120

Registration Number: NCT01087840

Locations: 🇦🇺
Sydney Sexual Health, Sydney Hospital, Sydney, New South Wales, Australia
🇦🇺
St. Vincent's Hospital, 390 Victoria Rd, Darlinghurst, Sydney, New South Wales, Australia

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir
Drug: ARV (non-raltegravir)

First Posted Date: 2010-01-14

Last Posted Date: 2015-10-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 482

Registration Number: NCT01048671

A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance

Not Applicable

Conditions: HIV
HIV Infections

Interventions: Drug: Raltegravir

First Posted Date: 2010-01-05

Last Posted Date: 2011-06-15

Lead Sponsor: Centers for Disease Control and Prevention, China

Target Recruit Count: 60

Registration Number: NCT01042652

Locations: 🇨🇳
Division of Treatment and Care, NCAIDS, China CDC, Beijing, Beijing, China

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

Phase 1

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: Raltegravir

First Posted Date: 2009-12-07

Last Posted Date: 2010-03-19

Lead Sponsor: Changi General Hospital

Target Recruit Count: 6

Registration Number: NCT01027182

Locations: 🇸🇬
Changi General Hospital, Singapore, Singapore

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Phase 4

Conditions: AIDS
Triple Class Failure
HIV-1 Adults Patients

First Posted Date: 2009-11-16

Last Posted Date: 2010-02-10

Lead Sponsor: Fundación Huésped

Target Recruit Count: 60

Registration Number: NCT01013987

Locations: 🇦🇷
Fundación Huésped, Ciudad de Buenos Aires, Argentina

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Phase 1

Completed

Conditions: Leukemia-Lymphoma, Adult T-Cell

Interventions: Drug: Bortezomib
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Raltegravir

First Posted Date: 2009-10-23

Last Posted Date: 2017-03-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT01000285

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Miami Hospital/Sylvester, Miami, Florida, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 3 locations

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir

First Posted Date: 2009-10-15

Last Posted Date: 2019-12-05

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 5

Registration Number: NCT00995241

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy